Relationship between expression and prognostic ability of PTEN, STAT3 and VEGF-C in colorectal cancer

Experimental and Therapeutic Medicine

Volumn 4, Issue 4, 2012, Pages 633-639

  Jin, Canhui ^a   Wang, Aihong ^a   Chen, Jianmin ^a   Liu, Xiaomin ^a   Wang, Gongping ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Colorectal cancer; Immunohistochemistry; Prognosis; PTEN; STAT3; VEGF C

Indexed keywords

ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; STAT3 PROTEIN; VASCULOTROPIN C;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 84865396632     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.651     Document Type: Article

References (29)

1. Higa R: Colorectal cancer: epidemiology and primary profilaxis. Acta Gastroenterol Latinoam 41: 70-73, 2011.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
3. Yoon YK, Kim HP, Han SW, Oh do Y, Im SA, Bang YJ and KimTY: KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog 49: 353-362, 2010.
4. Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, RiggsSB, Zomorodian N, Kabbinavar FF, Pantuck AJ and BelldegrunAS: Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev 18: 894-900, 2009.
5. Lee J, Kang WK, Park JO, Park SH, Park YS, Lim HY, KimJ, KongJ, Choi MG, Sohn TS, et al: Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS 117: 598-606, 2009.
6. Yokoyama Y, Sato S, Futagami M, Fukushi Y, Sakamoto T, UmemotoM and Saito Y: Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol 77: 413-418, 2000.
7. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, KrishnegowdaNK, Troyer DA and Ghosh PM: Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 13: 3860-3867, 2007.
8. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, HessKR, Myers JN, Hong YK, Yung WK and Steck PA: Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59: 1820-1824,1999.
9. Lee HS, Lee HK, Kim HS, Yang HK and Kim WH: Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 200: 39-46, 2003.
10. Zhang S and Yu D: PI(3)king apart PTEN's role in cancer. Clin Cancer Res 16: 4325-4330, 2010.
11. Hameed M, Lange KH, Andersen JL, Schjerling P, Kjaer M, Harridge SD and Goldspink G: The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men. J Physiol 555: 231-240, 2004.
12. Couffinhal T, Dufourcq P and Duplàa C: Beta-catenin nuclear activation: common pathway between Wnt and growth factor signaling in vascular smooth muscle cell proliferation? Circ Res 99: 1287-1289, 2006.
13. Zhang HY, Zhang Q, Zhang X, Yu C, Huo X, Cheng E, WangDH, Spechler SJ and Souza RF: Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol 300: G454-G460, 2011.
14. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, NagayasuT and SekineI: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 58: 833-838, 2005.
15. Liu JR, Wang Y, Zuo LF, Li FL, Wang Y and Liu JL: Expression and clinical significance of COX-2, p-Stat3, and p-Stat5 in esophageal carcinoma. Ai Zheng 26: 458-462, 2007.
16. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, YoshizakiA, Inoue K, Nagayasu T and Sekine I: Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. OncolRep15: 1445-1451, 2006.
17. Senft C, Priester M, Polacin M, Schröder K, Seifert V, Kögel D and Weissenberger J: Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol 101: 393-403, 2011.
18. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-ThomasS, Niu G, Kay H, Mulé J, Kerr WG, et al: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11: 1314-1321, 2005.
19. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, KukkE, Saksela O, Kalkkinen N and Alitalo K: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15: 1751, 1996.
20. Tanaka T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, KatadaT, Shiozaki M, Naganawa Y, Fujii Y and Takeyama H: Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res 29: 83, 2010.
21. Rinderknecht M and Detmar M: Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol 216: 347-354, 2008.
22. Han FH, Li HM, Zheng DH, He YL and Zhan WH: The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol 36: 1172-1179, 2010.
23. Yang H, Kim C, Kim MJ, Schwendener RA, Alitalo K, HestonW, Kim I, Kim WJ and Koh GY: Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer 10: 36, 2011.
24. Matsuura M, Onimaru M, Yonemitsu Y, Suzuki H, Nakano T, Ishibashi H, Shirasuna K and Sueishi K: Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells. Am J Pathol 175: 1709-1721, 2009.
25. Kodama M, Kitadai Y, Tanaka M, Kuwai T, Tanaka S, OueN, Yasui W and Chayama K: Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. Clin Cancer Res 14: 7205-7214, 2008.
26. Bednarek W, Wertel I and Kotarski J: Lymphangiogenesis in cancerous tumours. Ginekol Pol 79: 625-629, 2008 (In Polish).
27. Saharinen P, Tammela T, Karkkainen MJ and AlitaloK: Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 25: 387-395, 2004.
28. Park GS, Joo YE, Kim HS, Choi SK, Rew JS, Park CS and KimSJ: Expression of PTEN and its correlation with angiogenesis in gastric carcinoma. Korean J Gastroenterol 46: 196-203, 2005.
29. Zhao M, Liu F, Wang JY, Zhang WY, Gao FH and JiangB: Effects of JAK2/STAT3 signaling pathway on angiogenesis in non-small cell lung cancer. Zhonghua Yi Xue Za Zhi 91: 375-381, 2011 (In Chinese).